Search Results

Recent Publications
Manuscripts:

  • Cicero TJ, Ellis MS. Health outcomes and motivations of patients using no-prescription online pharmacies to purchase tramadol. Journal of Medical Internet Research. 2012(Dec 06);14(6)e174.

 

  • Cicero TJ, Surrat HL, Kurtz S, Ellis MS, Inciardi JA. Patterns of prescription opioid abuse and comorbidity in an aging treatment population. Journal of Substance Abuse Treatment. 2012;42:87-94.

 

  • Zosel A, Bartleson BB, Bailey JE, Lowenstein S, Dart RC. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS®) System. American Academy of Adolescent and Child Psychiatry. In Press
Abstracts - Posters - Platforms:

 

  • Dart RC, Adams E, Bucher-Bartelson B, Baker G, Pitner J, Vorsanger G. Trends in the non-medical use of tapentadol immediate release by college students. PAINWeek 2012. Las Vegas, NV. September 2012.

 

  • Brown KR, Severtson SG, Dart RC, RADARS® System Poison Center Group. RADARS® System poison center intentional exposures to OxyContin®: a look at the differences in rates of abuse via unintended routes before and after reformulation intervention. North American Congress of Clinical Toxicology Congress. Las Vegas, NV. October 2012.

 

  • Dart RC Classifying Abuse-Related Events: the RADARS System Experience. Abuse Liability Evaluation for Research, Treatment and Training Working Group. Washington, DC. November 2012.

 

  • Davis JM, Bucher-Bartelson B, Severtson SG, Dart RC, RADARS® System Poison Center Group. Regional differences in seasonal trends in suicide exposures to prescription opioids as reported to poison centers participating in the RADARS® System. North American Congress of Clinical Toxicology Congress. Las Vegas, NV. October 2012.

 

  • Davis J, Severtson SG, Bartelson BB, Muñoz A, Schneider MF, Surratt H, Chilcoat H, Coplan P, Green JL, Dart RC. Changes in diversion rates following the introduction of a reformulated extended release oxycodone product. American College of Emergency Physicians Scientific Assembly. Denver, CO. October 2012.

 

  • Davis J, Severtson SG, Bartelson BB, Muñoz A, Schneider MF, Surratt H, Chilcoat H, Coplan P, Green JL, Dart RC Changes in diversion rates following the introduction of a reformulated extended release oxycodone product. American Academy of Physical Medicine and Rehabilitation Annual Meeting. Atlanta, GA. November 2012.

 

  • Fischer LJ, Davis JM, Bucher-Bartelson B, Poppish L, Dart RC, RADARS® System Poison Center Group. Prescription opioid and stimulant use among pregnant women: surveillance by poison control centers participating in the RADARS® System. North American Congress of Clinical Toxicology Congress. Las Vegas, NV. October 2012.

 

  • Green JL. The impact of tamper resistant formulations on prescription drug abuse. National Association of State Controlled Substance Authorities (NASCA) Conference. Scottsdale, AZ. October 2012. Green JL. Intentional and Unintentional Prescription Opioid Exposures in Australia, Italy, Germany and the United States. North American Congress of Clinical Toxicology Congress. Las Vegas, NV. October 2012.

 

  • Green JL, Bucher-Bartelson B, Desel H, Ochsenfahrt G, Sesana F, Milanesi G, Brown J, Gunja N, Dart RC International Perspective on Prescription Stimulant Exposures Reported to Poison Centres from 2007-2011. North American Congress of Clinical Toxicology Congress. Las Vegas, NV. October 2012.

 

  • Lavonas EJ, Severtson G, Murrelle EL, Ruby J, Bucher-Bartelson B, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old: initial experience from the RADARS® System Poison Center Program. Association for Medical Education and Research in Substance Abuse Annual Meeting. Bethesda, MD. November 2012.

 

  • Lavonas EJ, Severtson G, Murrelle EL, Ruby J, Bucher-Bartelson B, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old. International Society for Pharmacoeconomics and Outcomes Research European Congress. Berlin, Germany. November 2012.

 

  • Lavonas EJ, Severtson G, Murrelle EL, Ruby J, Bucher-Bartelson B, Dart RC. Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old. American Academy of Addiction Psychiatry Annual Meeting. Aventura, FL. December 2012.

 

  • Lavonas E. Prescription Drug Monitoring Programs: evidence for effectiveness. FDA Drug Safety and Risk Management Advisory Committee Meeting. Silver Spring, MD.

 

  • Maremanni I, Green JL. Trends of opioid misuse and diversion: lessons for Europe from the USA. International Society of Addiction Medicine (ISAM) RBP Sponsored Symposium. Geneva, Switzerland. October 2012.

 

  • Severtson SG, Bartelson BB, Davis J, Muñoz A, Schneider MF, Coplan P, Chilcoat H, Green JL, Dart RC. Difference in rates of abuse following reformulation of extended release (ER) oxycodone using data from the RADARS® System Poison Center program. American College of Emergency Physicians Scientific Assembly. Denver, CO. October 2012.

 

  • Severtson SG, Bartelson BB, Davis J, Muñoz A, Schneider MF, Coplan P, Chilcoat H, Green JL, Dart RC. Difference in rates of abuse following reformulation of extended release (ER) oxycodone using data from the RADARS® System Poison Center program. American Academy of Physical Medicine and Rehabilitation Annual Meeting. Atlanta, GA. November 2012.

 

  • Winter EJ, Davis JM, Bucher-Bartelson B, Westberry R, Green JL, Lavonas EJ, Dart RC, RADARS® System Poison Center Group. Systematic misclassification in product-specific coding of poison center data: the example of buprenorphine in the RADARS® System poison center program. North American Congress of Clinical Toxicology Congress. Las Vegas, NV. October 2012.